Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari; Haris Ali; Yi-Bin Chen; Salman Fazal; Tara K. Gregory; Sarah M. Anand; Ahmad Naim; Dilan Paranagama; Valkal Bhatt; Amy Blithe; John F. DiPersio

doi:10.1182/BLOOD-2020-140541

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari
, Haris Ali
, Yi-Bin Chen
, Salman Fazal
, Tara K. Gregory
, Sarah M. Anand
, Ahmad Naim
, Dilan Paranagama
, Valkal Bhatt
, Amy Blithe
, John F. DiPersio

Medical College of Wisconsin
City of Hope National Medical Center
Harvard University
Allegheny Health Network
Colorado Blood Cancer Institute, Denver, CO
University of Michigan
Incyte
Washington University in St. Louis

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-140541
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD-2020-140541License: Unspecified

Cite this

@article{c63b36befd664ab4a703526d6602fc87,

title = "Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program",

author = "Parameswaran Hari and Haris Ali and Yi-Bin Chen and Salman Fazal and Gregory, \{Tara K.\} and Anand, \{Sarah M.\} and Ahmad Naim and Dilan Paranagama and Valkal Bhatt and Amy Blithe and DiPersio, \{John F.\}",

note = "Oral and Poster Abstracts 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I Diseases, GVHD, Immune Disorders 1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Brookfield, WI 2City of Hope Medical Center, Duarte, CA 3Massachusetts General Hospital, Boston, MA 4Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA 5Colorado Blood Cancer Institute, Denver, CO 6University of Michigan, Ann Arbor, MI 7Incyte Corporation, Wilmington, DE 8 Washington University School of Medicine in St.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-140541",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

AU - Hari, Parameswaran

AU - Ali, Haris

AU - Chen, Yi-Bin

AU - Fazal, Salman

AU - Gregory, Tara K.

AU - Anand, Sarah M.

AU - Naim, Ahmad

AU - Paranagama, Dilan

AU - Bhatt, Valkal

AU - Blithe, Amy

AU - DiPersio, John F.

N1 - Oral and Poster Abstracts 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I Diseases, GVHD, Immune Disorders 1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Brookfield, WI 2City of Hope Medical Center, Duarte, CA 3Massachusetts General Hospital, Boston, MA 4Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA 5Colorado Blood Cancer Institute, Denver, CO 6University of Michigan, Ann Arbor, MI 7Incyte Corporation, Wilmington, DE 8 Washington University School of Medicine in St.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper140541.html

U2 - 10.1182/BLOOD-2020-140541

DO - 10.1182/BLOOD-2020-140541

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Disciplines

Access to Document

Other files and links

Cite this